Breyanzi and Imdelltra head up May’s approvals, while camrelizumab’s CRL is a lowlight.

Pfizer moves to take PF-07934040 into its first clinical trial.

The company defends its cancer strategy, and says it's not a me-too developer.

The company’s vuso-vec looks similar to Amtagvi, and could have safety and convenience advantages.

Supply continues to cause headaches for radiopharmaceutical developers.

As the dust settles on ASCO the weekend’s immediate winners and losers emerge.